Mainz Biomed Gains Support for Pancreatic Cancer Test
BERKELEY, Calif. and MAINZ, Germany — Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneer in molecular genetic diagnostics aimed at early cancer detection, is excited to announce a significant funding milestone for its pancreatic cancer project. With support from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), a dedicated development bank in Germany, Mainz Biomed can now advance its innovative screening technology.
Funding Details and Expected Impact
Through the ISB’s Innovation and Technology Support Program, up to 50% of the total project costs will be covered. This governmental endorsement not only highlights the societal and scientific importance of Mainz Biomed’s non-invasive blood test for early pancreatic cancer detection but also accelerates the project's timeline, giving it a strong backing during the initial phases of development.
Significance of the Project
The funding awarded illustrates the critical need for improved diagnostics in cancer care, particularly for conditions like pancreatic cancer, known for its late-stage diagnoses. Mainz Biomed’s approach aims to close this gap, facilitating earlier treatment opportunities for patients.
“This support from the ISB is a strong vote of confidence in the potential of our technology and its role in enhancing early detection strategies,” commented Dr. Moritz Eidens, Chief Scientific Officer of Mainz Biomed.
Current Project Status and Collaborations
The project is presently in its feasibility phase. Collaborating with Crown Bioscience, Mainz Biomed is assessing a selection of mRNA biomarkers alongside a machine learning-driven algorithm. These efforts utilize genuine clinical blood samples, which are vital in establishing the test's effectiveness.
This research is part of Mainz Biomed’s broader strategy to expand its suite of accessible, non-invasive diagnostic tests tailored to various cancer types. By leveraging advanced technologies, the company hopes to transform cancer screenings into simpler, less invasive procedures.
About Mainz Biomed
Mainz Biomed specializes in creating market-ready molecular genetic diagnostic solutions for serious health conditions. Their flagship product, ColoAlert, is a non-invasive, easy-to-use test designed for early detection of colorectal cancer. Already available in Europe and the UAE, this product underscores the company’s commitment to developing useful diagnostic tools. Furthermore, Mainz Biomed is conducting a pivotal clinical study to gain FDA approval for the U.S. market.
Additionally, the company is advancing its innovative PancAlert test, an early-stage screening solution for pancreatic cancer. This test employs real-time Polymerase Chain Reaction (PCR) methodology to detect genetic biomarkers in stool samples, which further illustrates the commitment to pioneering cancer diagnostics.
Media and Investor Relations
For media inquiries, contact MC Services AG:
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please reach out via email at ir@mainzbiomed.com.
Frequently Asked Questions
What recent funding has Mainz Biomed received?
Mainz Biomed has secured public funding from ISB to support its pancreatic cancer screening project.
What is the focus of Mainz Biomed?
The company focuses on molecular genetic diagnostics, particularly aimed at early cancer detection.
What is the significance of the pancreatic cancer screening test?
This test aims to detect pancreatic cancer at a more treatable stage, which is often critical for patient outcomes.
What other diagnostic products does Mainz Biomed offer?
Mainz Biomed markets ColoAlert for colorectal cancer detection and is developing PancAlert for pancreatic cancer screening.
How is Mainz Biomed funded?
The company has received government support covering a significant portion of project costs, highlighting confidence in its technology.
